Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT.sub.1D receptor agonists
AssigneeMerck Sharp & Dohme Corp.
InventorsMark Stuart Chambers, Angus Murray MacLeod, Victor Giulio Matassa
Life of this patent
Estimating the term…
Loading patent…
AssigneeMerck Sharp & Dohme Corp.
InventorsMark Stuart Chambers, Angus Murray MacLeod, Victor Giulio Matassa
Estimating the term…
A class of 1,4-disubstituted piperazine derivatives, further substituted on one of the carbon atoms of the piperazine ring, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
A compound of formula I, or a pharmaceutically acceptable salt thereof:
A compound selected from:
A compound selected from:
Dependencies are inferred from the claim text.